[HTML][HTML] Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies

CT Harris, S Cohen - BioDrugs, 2024 - Springer
Monoclonal antibodies (mAbs) have transformed therapeutic strategies for various diseases.
Their high specificity to target antigens makes them ideal therapeutic agents for certain …

[HTML][HTML] Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability

H Bashour, E Smorodina, M Pariset, J Zhong… - Communications …, 2024 - nature.com
Designing effective monoclonal antibody (mAb) therapeutics faces a multi-parameter
optimization challenge known as “developability”, which reflects an antibody's ability to …

Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability

H Bashour, E Smorodina, M Pariset, J Zhong, R Akbar… - bioRxiv, 2023 - biorxiv.org
Designing effective monoclonal antibody (mAb) therapeutics face a significant challenge
known as" developability", which reflects an antibody's ability to progress through …